In addition, PD-L1 expression by immunohistochemistry is included in FDA labels and NCCN guidelines for advanced NSCLC but was not included in this analysis as PD-L1 IHC is not a component of either assay. The gene discussed is CD274; the disease is non-small cell lung carcinoma.